Beam TherapeuticsvsEli Lilly and Company

BEAM and LLY stock compared: price, dividend, valuation and results, from SEC filings.

BEAM

Beam Therapeutics Inc.

$20.94

Value $2.1B

-4.99%
BEAM's page

LLY

Eli Lilly and Company

$1,431.67

Value $1.35T

+1.14%
LLY's page

Beam Therapeutics (BEAM) has a market value of $2.1B and Eli Lilly and Company (LLY) $1.35T. Over the last year, with dividends, BEAM moved +4.4% and LLY +42.9%. Dividend yield: BEAM none, LLY 0.44%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    BEAM$2.1B

    LLY$1.35T

    LLY is 633 times BEAM

  • Revenue, 12 months

    BEAM$147M

    LLY$86.5B

    LLY is 590 times BEAM

  • Net income, 12 months

    BEAM-$108M

    LLY$27.6B

  • Operating margin

    BEAM-267.7%

    LLY–

  • ROIC

    BEAM-28.7%

    LLY35.5%

    64.2 points apart

  • P/E

    BEAM–

    LLY49.0

  • Dividend yield

    BEAM0.0%

    LLY0.4%

    0.4 points apart

  • 5-year return

    BEAM-75.2%

    LLY+480.4%

    555.6 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

BEAM-75.2%

LLY+480.4%

020040060020222023202420252026
Returns by period
PeriodBEAMWith dividendsLLYWith dividends
1 year since November 12, 2025+4.4%Price +4.4%+42.9%Price +41.8%
3 years since November 13, 2023+4.1%+1.3% a yearPrice +4.1%+140.8%+34.0% a yearPrice +135.6%
5 years since November 12, 2021-75.2%-24.3% a yearPrice -75.2%+480.4%+42.2% a yearPrice +455.9%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

BEAMBeam TherapeuticsLLYEli Lilly and Company

Valuation

BEAMLLY
Valuation
Price$20.94$1,431.67
Market value$2.1B$1.35T
Enterprise value (EV)$1.2B$1.40T
P/E–49.0
P/E, 5-year median–49.9
P/B2.233.5
EV/EBIT–40.1
Free cash flow yield–1.5%

Results and growth

BEAMLLY
Results and growth
Revenue, 12 months$147M$86.5B
Net income, 12 months-$108M$27.6B
Free cash flow, 12 months-$398M$19.7B
Earnings per share, 12 months-$0.87$30.81
Revenue growth, year on year120.0%44.7%
Revenue growth a year, past+466.3%over 5 years+21.6%over 5 years
EPS growth a year, past–+27.6%over 5 years

Margins and returns on capital

BEAMLLY
Margins and returns on capital
Gross margin–83.6%
Operating margin-267.7%–
Net margin-73.9%31.9%
ROIC-28.7%35.5%
ROE-10.0%88.6%

Balance sheet

BEAMLLY
Balance sheet
Cash$1.0B$4.9B
Total debt$244M$49.5B
Net debt / EBITDA–1.2
Interest cover–38.9×

Dividends and buybacks

BEAMLLY
Dividends and buybacks
Dividend yield–0.4%
Dividend per share, 12 months–$6.34
Dividend growth a year, past–+15.2%over 5 years
Buyback yield–0.3%
Shareholder yield–0.7%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: BEAM or LLY

Didn't find what you were looking for?

Ask us
Which is bigger, Beam Therapeutics or Eli Lilly and Company?

By market value, Eli Lilly and Company ($1.35T) is about 633.2 times Beam Therapeutics ($2.1B), at today's prices.

How did BEAM and LLY stock do over the last 5 years?

Since November 12, 2021, BEAM's price moved -75.2% and LLY's +455.9%. With dividends: BEAM -75.2% (-24.3% a year), LLY +480.4% (+42.2% a year). Past returns do not predict future ones.

Which pays the higher dividend, BEAM or LLY?

The dividend yield at today's price is none for Beam Therapeutics and 0.44% for Eli Lilly and Company. Over the last twelve months they paid – and $6.34 per share.

Which has the higher profit margins, Beam Therapeutics or Eli Lilly and Company?

Over the last twelve months, the net margin was -73.9% for Beam Therapeutics and 31.9% for Eli Lilly and Company, and the operating margin -267.7% and –. Revenue was $147M and $86.5B.

Which is the better investment, Beam Therapeutics or Eli Lilly and Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.